Effects of valsartan and sacubitril: A Synthesis of Findings from 26 Studies

  1. Home
  2. Effects of valsartan and sacubitril
This information is not medical advice and is not a substitute for diagnosis or treatment by a physician.Data sources and disclaimers (data limitations, copyright, etc.)The analysis on "Effects of valsartan and sacubitril: A Synthesis of Findings from 26 Studies" on this page is based on PubMed data provided by the U.S. National Library of Medicine (NLM). However, NLM does not endorse or verify these analyses.

This analysis is based on research papers included in PubMed, but medical research is constantly evolving and may not fully reflect the latest findings. There may also be biases towards certain research areas.

This information is not medical advice and is not a substitute for diagnosis or treatment by a physician. If you have concerns about "Effects of valsartan and sacubitril: A Synthesis of Findings from 26 Studies", please consult your doctor.

For NLM copyright information, please see Link to NLM Copyright Page
PubMed data is obtained via Hugging Face Datasets: Link to DatasetPlease check the disclaimer.
This page's analysis is based on PubMed data provided by the U.S. National Library of Medicine (NLM).
Original Abstract of the Article

Major Research Findings

Several studies suggest that valsartan and sacubitril combination therapy is a promising option for treating heart failure. 2 indicates that valsartan and sacubitril combination therapy is a promising new drug for heart failure. 21 investigated the effects of valsartan and sacubitril combination therapy on heart failure signs and symptoms and prognosis, and reported improvements in heart failure symptoms. 8 evaluated the pharmacokinetics and pharmacodynamics of valsartan and sacubitril combination therapy in peritoneal dialysis patients, suggesting that it may be safely used in patients with impaired kidney function. 20 shows the potential benefits and safety of valsartan and sacubitril combination therapy in patients with HFpEF using a meta-analysis. 25 suggests that valsartan and sacubitril combination therapy may be effective in inhibiting cardiac fibrosis. 9 suggests that valsartan and sacubitril combination therapy may be effective in improving atrial fibrillation. 4 investigated the effects of valsartan and sacubitril combination therapy on serum lipids in heart failure patients, reporting effects such as reduced triglycerides. 19 investigated the effects of valsartan and sacubitril combination therapy in a heart failure model after myocardial infarction, suggesting that it may be effective in suppressing ventricular arrhythmias. 10 reviews the results of key clinical trials demonstrating the effectiveness of valsartan and sacubitril combination therapy in treating heart failure. 14 suggests that valsartan and sacubitril combination therapy may be effective in improving exercise tolerance in heart failure patients. 17 reviews the effectiveness and evidence of valsartan and sacubitril combination therapy in treating heart failure. 24 reviews the effects and risks of long-term use of valsartan and sacubitril combination therapy. 15 suggests that valsartan and sacubitril combination therapy may be effective in improving the cardiometabolic profile of diabetic patients. 18 reviews studies showing the effectiveness of valsartan and sacubitril combination therapy in treating heart failure. 7 investigated the effects of valsartan and sacubitril combination therapy in heart failure, finding no difference in effects between men and women. 5 reviews the therapeutic effects of valsartan and sacubitril combination therapy in chronic heart failure. 26 suggests that valsartan and sacubitril combination therapy may be effective in suppressing ventricular arrhythmias. 13 reviews studies showing the effectiveness of valsartan and sacubitril combination therapy in treating heart failure and hypertension. 23 suggests that valsartan and sacubitril combination therapy may be effective in treating heart failure and hypertension. 16 suggests that valsartan and sacubitril combination therapy may be effective in inhibiting diabetic nephropathy. 12 suggests that valsartan and sacubitril combination therapy may be effective in controlling the cardiovascular system. 3 suggests that valsartan and sacubitril combination therapy may be effective in inhibiting the deterioration of kidney function in diabetic patients. 11 is a meta-analysis that evaluates the effectiveness and safety of valsartan and sacubitril combination therapy in treating heart failure. 22 reviews hormone therapy for treating heart failure. 6 investigated the therapeutic effects of valsartan and sacubitril combination therapy in patients with acute heart failure.

Benefits and Risks

Benefit Summary

Valsartan and sacubitril combination therapy has been shown to reduce the risk of death and hospitalization from heart failure. 2 , 10 It is also expected to improve heart failure symptoms, especially shortness of breath and fatigue. 21 In addition, it has been reported to have blood pressure lowering effects and improve heart structure and function. 9 、 14 、 15 These effects are thought to be due to valsartan and sacubitril combination therapy dilating blood vessels in the heart, reducing the burden on the heart. 10 It is also expected to suppress the worsening of complications such as diabetes and kidney disease in patients with those complications. 15 、 12 、 16 、 3

Risk Summary

Valsartan and sacubitril combination therapy is generally considered a safe drug, but some side effects have been reported. 24 The most common side effects are dizziness, headache, and low blood pressure. 12 Rarely, cough, rash, and liver dysfunction may occur. 24 In patients with impaired kidney function, valsartan and sacubitril combination therapy may accumulate in the body, increasing the risk of side effects. 8 、 12 Also, valsartan and sacubitril combination therapy should not be used by pregnant or breastfeeding women. 24 When using valsartan and sacubitril combination therapy, it is important to consult your doctor and take it according to their instructions.

Comparison of Studies

Commonalities in Studies

Many studies have shown that valsartan and sacubitril combination therapy is effective in treating heart failure. 2 、 21 、 20 、 9 、 4 、 19 、 10 、 14 、 17 、 24 、 15 、 18 、 7 、 5 、 26 、 13 、 23 、 16 、 12 、 3 、 11 、 22 Furthermore, many studies have shown that valsartan and sacubitril combination therapy is more effective than other heart failure medications. 2 、 10 、 11

Differences in Studies

Studies have reported different effects and side effects of valsartan and sacubitril combination therapy. 24 For example, 8 evaluated the pharmacokinetics and pharmacodynamics of valsartan and sacubitril combination therapy in patients with impaired kidney function, suggesting that it may be safely used in patients with impaired kidney function. On the other hand, 12 states that in patients with impaired kidney function, valsartan and sacubitril combination therapy may accumulate in the body, increasing the risk of side effects. As different results have been obtained in different studies, decisions regarding the use of valsartan and sacubitril combination therapy should be made carefully in consultation with a doctor.

Consistency and Contradictions in Results

Valsartan and sacubitril combination therapy has been shown to reduce the risk of death and hospitalization from heart failure. 2 、 10 It is also expected to improve heart failure symptoms. 21 However, the effects of valsartan and sacubitril combination therapy may vary from patient to patient. 24 For example, in patients with impaired kidney function, valsartan and sacubitril combination therapy may accumulate in the body, increasing the risk of side effects. 8 、 12 Therefore, it is important to consult your doctor and take valsartan and sacubitril combination therapy according to their instructions.

Notes on Application in Real Life

Valsartan and sacubitril combination therapy is a promising option for treating heart failure, but it is not effective for all patients. 24 When using valsartan and sacubitril combination therapy, it is important to consult your doctor and consider your own situation and risks to choose the appropriate treatment. 12 Also, valsartan and sacubitril combination therapy can interact with other drugs. 24 Therefore, it is important to tell your doctor about all the medications you are taking and take them according to their instructions.

Current Research Limitations

There is still not enough research on valsartan and sacubitril combination therapy. 24 In particular, research on long-term effects and safety is lacking. 24 Also, valsartan and sacubitril combination therapy is not effective for all heart failure patients. 24 Therefore, it cannot be definitively stated that valsartan and sacubitril combination therapy is the appropriate treatment for all patients.

Future Research Directions

Further research is needed on the long-term effects and safety of valsartan and sacubitril combination therapy. 24 Research is also important to identify patients for whom valsartan and sacubitril combination therapy is effective. 24 Furthermore, research is needed to reduce the side effects of valsartan and sacubitril combination therapy. 24

Conclusion

Valsartan and sacubitril combination therapy is a promising option for treating heart failure, but it is not effective for all patients. 24 When using valsartan and sacubitril combination therapy, it is important to consult your doctor and consider your own situation and risks to choose the appropriate treatment. 12

Literature analysis of 26 papers
Positive Content
25
Neutral Content
1
Negative Content
0
Article Type
3
1
0
9
25
1.

[Doubleblind study with the novel antidepressant viloxazine versus imipramine in 50 in-patients (author's transl)].

Author: FloruL, CzarnyG, TegelerJ

Effective for depression
Few side effects
Rapid onset
Well tolerated
Fatigue
Hypertension
Sleep disturbances

Viloxazine was a very active and well-tolerated thymoleptic substance in 50 depressive patients, with a more rapid onset of effect and fewer side effects compared to imipramine.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Controlled Clinical TrialA clinical trial that evaluates the effectiveness of a treatment by comparing a group that receives the intervention with a group that receives a placebo or standard treatment.
English AbstractA summary of a research paper/publication written in English for a wider audience.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : German

2.

Pharmacology of heart failure: From basic science to novel therapies.

Author: LotherAchim, HeinLutz

Improved heart failure

This review discusses the current pharmacological therapy of chronic heart failure with reduced ejection fraction. It covers the updated clinical guidelines, new drugs in clinical development, and innovative drug targets emerging from preclinical studies.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

3.

Effects of sacubitril/valsartan versus valsartan on renal function in patients with and without diabetes and heart failure with preserved ejection fraction: insights from PARAGON-HF.

Author: PeikertAlexander, VaduganathanMuthiah, Mc CauslandFinnian, ClaggettBrian L, ChaturSafia, PackerMilton, PfefferMarc A, ZannadFaiez, LefkowitzMartin P, PieskeBurkert, DüngenHans-Dirk, McMurrayJohn J V, SolomonScott D

Renal function protection

Diabetes is associated with a faster rate of renal function decline in patients with heart failure (HF). This study assessed whether sacubitril/valsartan attenuates the deterioration of renal function in HF with preserved ejection fraction (HFpEF).

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

4.

Effects of Sacubitril/Valsartan on Serum Lipids in Heart Failure With Preserved Ejection Fraction.

Author: SelvarajSenthil, ClaggettBrian L, PackerMilton, ZannadFaiez, AnandInder S, PieskeBurkert, ZhaoZiqiang, ShiVictor C, LefkowitzMartin P, McMurrayJohn J V, SolomonScott D

Increased high-density lipoprotein
Reduced triglycerides

Sacubitril/valsartan, a combination drug used to treat heart failure with preserved ejection fraction, was found to significantly reduce triglycerides compared to valsartan alone. This effect was more pronounced in patients with elevated baseline triglyceride levels. Sacubitril/valsartan also modestly increased high-density lipoprotein cholesterol and low-density lipoprotein cholesterol levels. The changes in lipid levels may be related to the drug's effects on natriuretic peptide activity.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

5.

Chronic heart failure: advances in pharmacological treatment and future perspectives.

Author: KusterGabriela M, PfisterOtmar

Effective in heart failure

This abstract reviews recent advances in the diagnosis and pharmacological management of heart failure, including the use of angiotensin II receptor/neprilysin inhibitors (ARNIs) and sodium-glucose-co-transporter 2 (SGLT2) inhibitors.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

6.

The Relationship between Angiotensin-Neprilysin Treatment, Echocardiographic Parameters, and NT-proBNP Levels in HFpEF Patients with Acute Decompensated Heart Failure.

Author: ZhangXiaoliang, YangSong, XuZhonglin

Cardiac function
HFpEF

This randomized controlled trial of patients with preserved ejection fraction (HFpEF) hospitalized due to acute decompensated heart failure (ADHF) found that sacubitril-valsartan treatment, which lowered NT-proBNP levels and improved cardiac function, was more effective than enalapril.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Retracted PublicationCases where a publication has been formally withdrawn due to the discovery of serious errors or misconduct.

Language : English

7.

Effects of Sacubitril-Valsartan Versus Valsartan in Women Compared With Men With Heart Failure and Preserved Ejection Fraction: Insights From PARAGON-HF.

Author: McMurrayJohn J V, JacksonAlice M, LamCarolyn S P, RedfieldMargaret M, AnandInder S, GeJunbo, LefkowitzMarty P, MaggioniAldo P, MartinezFelipe, PackerMilton, PfefferMarc A, PieskeBurkert, RizkalaAdel R, SabarwalShalini V, ShahAmil M, ShahSanjiv J, ShiVictor C, van VeldhuisenDirk J, ZannadFaiez, ZileMichael R, CikesMaja, GoncalvesovaEva, KatovaTzvetana, KosztinAnamaria, LelonekMalgorzata, SweitzerNancy, VardenyOrly, ClaggettBrian, JhundPardeep S, SolomonScott D

Heart failure treatment
Sacubitril-valsartan
Heart failure

Sacubitril-valsartan seemed to reduce the risk of heart failure hospitalization more in women than in men compared with valsartan in patients with heart failure with preserved ejection fraction (HFpEF).

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

8.

Pharmacokinetics and pharmacodynamics of sacubitril/valsartan in peritoneal dialysis patients.

Author: HeYi, JinYing, XueHen, LiuRunhan, ZhangMengyu, LiaoRuoxi, ChenMaoli, ZhouXueli, HeXueqin, QinMin, LiKuo, ZouHuiqun, GanYing, WangZhenlei, ZhengLi, ZhongHui, FuPing

This study investigates the pharmacokinetics and pharmacodynamics of sacubitril/valsartan in peritoneal dialysis patients with hypertension or heart failure.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

9.

Sacubitril/valsartan attenuates atrial electrical and structural remodelling in a rabbit model of atrial fibrillation.

Author: LiLu-Yi-Fei, LouQi, LiuGuang-Zhong, LvJia-Chen, YunFeng-Xiang, LiTian-Kai, YangWen, ZhaoHong-Yan, ZhangLi, BaiNan, ZhanCheng-Chuang, YuJia, ZangYan-Xiang, LiWei-Min

Reduced atrial fibrillation

Sacubitril/valsartan, a drug used for heart failure, was found to attenuate atrial electrical remodeling and improve structural remodeling in rabbits with atrial fibrillation (AF). The drug reversed changes in calcium levels and expression of related proteins in heart cells, suggesting a potential benefit for AF patients.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

11.

Efficacy and safety of sacubitril-valsartan in heart failure: a meta-analysis of randomized controlled trials.

Author: ZhangHongzhou, HuangTieqiu, ShenWen, XuXiuxiu, YangPingping, ZhuDan, FangHaiyang, WanHongbing, WuTao, WuYanqing, WuQinghua

HF treatment
Hypertension treatment

This meta-analysis assessed and compared the effect and adverse events of sacubitril-valsartan, valsartan, and enalapril in patients with heart failure (HF).

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

13.

Role of neprilysin inhibitor combinations in hypertension: insights from hypertension and heart failure trials.

Author: BavishiChirag, MesserliFranz H, KadoshBernard, RuilopeLuis M, KarioKazuomi

heart failure treatment
hypertension treatment
ventricular unloading

This review discussed the mechanism of action, pharmacokinetics, and pharmacodynamics of LCZ696 (Valsartan/sacubitril) and its use in the treatment of hypertension.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

18.

Effects of Sacubitril/Valsartan (LCZ696) on Natriuresis, Diuresis, Blood Pressures, and NT-proBNP in Salt-Sensitive Hypertension.

Author: WangTzung-Dau, TanRu-San, LeeHae-Young, IhmSang-Hyun, RheeMoo-Yong, TomlinsonBrian, PalParasar, YangFan, HirschhornElizabeth, PrescottMargaret F, HinderMarkus, LangenickelThomas H

Blood pressure control
SSH management

Sacubitril/valsartan, a combination drug, was compared with valsartan alone in Asian patients with salt-sensitive hypertension (SSH). Sacubitril/valsartan resulted in greater short-term increases in natriuresis and diuresis, leading to superior blood pressure control compared with valsartan. These findings suggest that sacubitril/valsartan may be a more effective treatment for SSH.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : English

19.

LCZ696 Therapy Reduces Ventricular Tachyarrhythmia Inducibility in a Myocardial Infarction-Induced Heart Failure Rat Model.

Author: ChangPo-Cheng, LinShien-Fong, ChuYen, WoHung-Ta, LeeHui-Ling, HuangYu-Chang, WenMing-Shien, ChouChung-Chuan

HF reduction

This study evaluated the effects of LCZ696 on cardiac electrophysiology remodeling in animal models.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

20.

Sacubitril/valsartan reduces cardiac decompensation in heart failure with preserved ejection fraction: a meta-analysis.

Author: BasileChristian, PaolilloStefania, GargiuloPaola, MarzanoFederica, AsileGaetano, ParlatiAntonio Luca Maria, ChiricoAlfonsina, NardiErmanno, BuonocoreDavide, ColellaAngela, Perrone-FilardiPasquale

HF decompensation reduction
HFpEF treatment
Hypotension

This meta-analysis examined the clinical benefits and safety of sacubitril-valsartan for heart failure (HF) patients with preserved ejection fractions (HFpEF). Sacubitril-valsartan was found to significantly reduce the rate of HF decompensation events compared to valsartan. However, it was also associated with an increased risk of hypotension.

Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

21.

Burden of Heart Failure Signs and Symptoms, Prognosis, and Response to Therapy: The PARAGON-HF Trial.

Author: JeringKarola, ClaggettBrian, RedfieldMargaret M, ShahSanjiv J, AnandInder S, MartinezFelipe, SabarwalShalini V, SeferovićPetar M, Kerr SaraivaJose F, KatovaTzvetana, LefkowitzMarty P, PfefferMarc A, McMurrayJohn J V, SolomonScott D

HF symptom reduction
Sacubitril/valsartan efficacy

A high burden of heart failure (HF) signs and symptoms, particularly orthopnea and rales, was associated with a higher risk of adverse cardiovascular events in patients with HF with preserved ejection fraction (HFpEF). Sacubitril/valsartan did not significantly decrease the overall burden of HF signs and symptoms, but it reduced exertional dyspnea.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

22.

Hormone treatments in congestive heart failure.

Author: LeiLei, MaoYuanjie

CHF treatment
Cardioprotective
Heart failure
Liver disease
Weight gain

This review discusses the therapeutic effects of several key hormones in congestive heart failure (CHF), including the newly invented dual-acting drug valsartan/sacubitril, growth hormone, thyroid hormone, vasopressin antagonists, and incretin-based therapies.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

23.

LCZ696 (Valsartan/Sacubitril)--A Possible New Treatment for Hypertension and Heart Failure.

Author: AndersenMathilde Borring, SimonsenUlf, WehlandMarkus, PietschJessica, GrimmDaniela

Blood pressure reduction
Heart failure treatment
Mortality and morbidity reduction
Not specified

LCZ696, a dual-acting drug combining valsartan and sacubitril, showed greater blood pressure reductions and decreased mortality and morbidity in patients with heart failure with reduced ejection fraction compared to current treatments. It also lowered blood pressure and NT-pro-BNP levels in patients with heart failure with preserved ejection fraction.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

25.

Network model-based screen for FDA-approved drugs affecting cardiac fibrosis.

Author: ZeiglerAngela C, ChandrabhatlaAnirudha S, ChristiansenSteven L, NelsonAnders R, HolmesJeffrey W, SaucermanJeffrey J

Cardiac fibrosis treatment
Drug repurposing

A systems pharmacology approach combining network modeling and drug-target interactions identified galunisertib as a potential inhibitor of cardiac fibrosis. The model also predicted the mechanism of action of other drugs.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.

Language : English

26.

Effects of angiotensin-neprilysin inhibition compared to angiotensin inhibition on ventricular arrhythmias in reduced ejection fraction patients under continuous remote monitoring of implantable defibrillator devices.

Author: de DiegoCarlos, González-TorresLuis, NúñezJosé María, Centurión IndaRaúl, Martin-LangerwerfDavid A, SangioAntonio D, ChochowskiPiotr, CasasnovasPilar, BlazquézJulio C, AlmendralJesús

Decreased ventricular arrhythmias
Not specified

This study explored the effect of angiotensin-neprilysin inhibition on ventricular arrhythmias compared to angiotensin inhibition in patients with reduced ejection fraction heart failure (rEFHF). Angiotensin-neprilysin inhibition significantly decreased nonsustained ventricular tachycardia episodes, sustained ventricular tachycardia, and appropriate ICD shocks compared to angiotensin inhibition.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Observational StudyResearch that observes and collects data on participants' behavior and outcomes in their natural state, without intervention.

Language : English

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.